Eli Lilly (LLY)
(Delayed Data from NYSE)
$762.66 USD
+8.49 (1.13%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $762.65 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Eli Lilly (LLY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$741.71 | $950.00 | $525.00 | -1.65% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for Eli Lilly comes to $741.71. The forecasts range from a low of $525.00 to a high of $950.00. The average price target represents a decline of 1.65% from the last closing price of $754.17.
Analyst Price Targets (21)
Broker Rating
Eli Lilly currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 22 recommendations.
Of the 22 recommendations deriving the current ABR, 19 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 86.36% and 4.55% of all recommendations. A month ago, Strong Buy made up 86.36%, while Buy represented 4.55%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 18 | 17 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.21 | 1.23 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/7/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
1/23/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
1/3/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
12/21/2023 | Daiwa America | Research Department | Not Available | Strong Buy |
11/29/2023 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
11/8/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/17/2023 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
9/4/2023 | Berenberg Bank | Kerry Holford | Strong Buy | Strong Buy |
8/9/2023 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 22 |
Average Target Price | $741.71 |
LT Growth Rate | 36.70% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 191 of 252 |
Current Quarter EPS Est: | 2.56 |